REGISTER
Hengrui Wins Approval for First-in-Class SHR-1701
Hengrui’s rilvegostomig alfa analogue SHR-1701, a dual PD-L1/TGF-betaRII fusion protein, has been approved in China for first-line treatment of PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma with chemotherapy. Phase III results showed clear gains in survival, progression-free survival and response rate.

On January 7, the NMPA website showed that Hengrui’s Class 1 new drug Ralafup-α Injection (SHR-1701) was approved in China in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of patients with PD-L1-positive (CPS greater than or equal to 1) locally advanced unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma as determined by a fully validated test.

SHR-1701 is an anti-PD-L1/TGF-betaRII bifunctional fusion protein independently developed by Hengrui with proprietary intellectual property rights. It can promote activation of effector T cells while effectively improving immunoregulation in the tumor microenvironment, thereby enhancing immune killing of tumor cells.

In June 2024, SHR-1701 met the prespecified primary endpoint in the Phase III SHR-1701-III-307 trial in gastric cancer. This randomized, double-blind, multicenter Phase III study evaluated SHR-1701 plus chemotherapy versus placebo plus chemotherapy in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with overall survival as the primary endpoint. The principal investigator was Prof. Shen Lin of Peking University Cancer Hospital.

At the 2024 ESMO Congress, Hengrui presented the trial data as an oral presentation. As of May 20, 2024, 365 patients were enrolled in the SHR-1701 group and 366 in the placebo group, with a median follow-up of 8.5 months.

Among patients with PD-L1 CPS greater than or equal to 5, 93 overall survival events (37.8%) occurred in the SHR-1701 group versus 149 (60.1%) in the placebo group. Median overall survival was 16.8 months versus 10.4 months, respectively (HR=0.53; p<0.0001), meeting statistical significance. Progression-free survival events occurred in 133 patients (54.1%) versus 180 patients (72.6%), with median PFS of 7.6 months versus 5.5 months (HR=0.52). Confirmed ORR was 56.5% versus 32.7%, a difference of 23.8%, and duration of response was 10.2 months versus 5.1 months.

In the intention-to-treat population, 153 overall survival events (41.9%) occurred in the SHR-1701 group and 208 (56.8%) in the placebo group. Median overall survival was 15.8 months versus 11.2 months (HR=0.66; p<0.0001), also showing statistical significance. Progression-free survival events occurred in 202 patients (55.3%) versus 256 patients (69.9%), with median PFS of 7.0 months versus 5.5 months (HR=0.57). Confirmed ORR was 53.4% versus 32.8%, a difference of 20.6%, and duration of response was 8.5 months versus 5.3 months.

Beyond advanced gastric cancer, Hengrui is also studying SHR-1701 in rectal cancer, non-small cell lung cancer, and multiple other indications to evaluate its antitumor activity across solid tumors.

According to the Insight database, SHR-1701 is the first PD-L1/TGF-beta dual-target agent approved globally. Other developers active in the same field include Merck, Chia Tai Tianqing, and Huaota Biopharmaceuticals, with the fastest competing programs already in Phase III clinical development.

0
0
Loading